Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Immatics N.V.NASDAQ: IMTX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables outflow grows to €10.57M

Q1 FY2026 accounts payables was €10.57M, compared with €0 a year earlier. Trailing-twelve-month accounts payables was -€11.74M.

Context

  • Accounts payables amounted to 74.9% of revenue in FY2025, up 74.9 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near €10.57M or moves back toward the trailing-twelve-month quarterly average of -€2.94M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€10.57M+147.4% QoQ
Last fiscal yearDec 2025
-€36.13M— YoY
LTMMar 2026
-€11.74M-29.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

EUR · from the cash flow

Latest · FY2025
(36.13M) EUR
Year-over-year change
—

Accounts Payables vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.4% is the 4th highest of 11, against a peer median of -84.7%.
  • Accounts payables amounts to 31.5% of revenue for IMTX, versus a peer median of 3.2%.
IMTX Competitors
Accounts Payables for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€834.85M EUR-430.3%—31.6%
LEGNLegend Biotech CorporationLTM Sep 2026$26.31M USD-138.8%-15.0%1.9%
IMTXImmatics N.V.LTM Mar 2026€11.74M EUR-29.4%—31.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.52M USD-185.2%—27.6%
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.7M USD+135.6%—5477.4%
CLLSCellectis S.A.LTM Mar 2026$1.34M USD-181.1%—2.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$1M USD+148.6%—4.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$747K USD-49.2%-22.8%3.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$232K USD-67.8%——
IMCRImmunocore Holdings plcLTM Mar 2026$193.53K USD-101.5%—0.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$17K USD+117.0%—0.0%
Peer median (excluding IMTX) —-84.7%-18.9%3.2%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.